Study of a new injection for stubborn lupus
Part of Immune system & allergy, Skin clinical trials.
This study tests an experimental injection called ZM001 for people with severe lupus that hasn't improved with standard treatments. The goal is to see if this new therapy can help control the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a confirmed lupus diagnosis using standard criteria.
- Your lupus must still be active (scoring at least 7 on a lupus activity scale) despite trying at least two months of standard treatments, including steroids, immunosuppressants, and a biologic like belimumab or rituximab.
- You must be between 18 and 70 years old.
- Your blood counts must meet minimum levels (e.g., certain counts of red cells, white cells, and platelets).
- You cannot have had CAR-T therapy, a stem cell transplant, or an organ transplant before.
- You must not have active infections like hepatitis, HIV, or tuberculosis.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an investigational injection called CM313 for people with active lupus (systemic lupus erythematosus). It aims to see if the drug can help reduce lupus symptoms and control the disease.
This study tests a new drug called LBL-047 in healthy people and in people with mild to moderate lupus. It helps check if the drug is safe and how the body processes it. Participating may help find better treatments for lupus.
This trial tests an investigational drug called AZD5492 for people with active lupus, inflammatory myositis, or rheumatoid arthritis who haven't responded well to other treatments. It aims to see if the drug is safe and how it works in the body.
This trial is testing a new investigational drug called QLS4131 in people with systemic lupus erythematosus (SLE), an autoimmune disease where the immune system attacks healthy tissues. The goal is to see if it is safe and effective in reducing disease activity.
This trial tests a new antibody treatment, GNC-038, for people with moderate to severe lupus. It aims to see if it's safe and effective. You must have stable lupus treatment and active B cells in your blood.
This study tests a new medicine called Dapirolizumab Pegol (given as an infusion) for people with moderate to severe lupus (SLE) that is not well controlled despite standard treatments. It aims to see if the drug can reduce lupus activity and prevent flares.
Hear when a new Systemic Lupus Erythematosus trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.